Cruinn Diagnostics Acquired Katalyst Diagnostics
The deal expands the firm's UK diagnostic reach and adds established NHS customer relationships.
Updated on Sept. 24, 2026 in Healthcare
Live Poll
Do you believe industry mergers and acquisitions generally lead to better service for customers?
Cruinn Diagnostics has finalized the acquisition of Katalyst Diagnostics to broaden its footprint in the UK market. The combined business now serves clinical customers with expanded point-of-care solutions.
Why it matters
This move provides Cruinn with direct access to established NHS accounts and complementary diagnostic technologies. It marks a strategic shift for the company to scale its operations across the UK and Ireland.
The combined entity now employs more than 100 people and generates over €50 million in annual revenue. The group has set a target to grow total revenue to €150 million over the coming years.
The players
Cruinn Diagnostics
An Ireland-based diagnostics provider leveraging a regional platform to scale its portfolio of clinical solutions.
Katalyst Diagnostics
A UK-based provider of point-of-care diagnostic solutions serving clinical customers and the NHS.
Afsheen Khan
The managing director of Katalyst Diagnostics who remains in the role following the acquisition.
The details
Katalyst Diagnostics will continue to operate under its existing leadership, with Afsheen Khan remaining as managing director. Cruinn utilizes its established Irish platform to integrate the new portfolio and support expanded service levels. The deal allows for the cross-selling of diagnostic products to the existing UK clinical and NHS customer base.
Timeline
September 24, 2026: The acquisition was formally announced.
Market Landscape
The acquisition follows a documented industry trend of diagnostics firms seeking to aggregate specialized point-of-care assets to gain scale in the UK and Ireland. This consolidation mirrors efforts by regional providers to capture larger market shares through diversified service portfolios.
Operators in the diagnostics space should monitor how the integration affects competitive pricing and service delivery in the NHS procurement chain. Keep watch for further M&A activity as the group pursues its €150 million revenue goal.
The takeaway
Strategic acquisitions remain a key mechanism for diagnostics firms to quickly secure government-backed customer relationships. Leaders should track the firm's stated plans to expand into continental European markets as a signal of its competitive trajectory.
Further reading
For broader trends in medical service consolidation, review the latest updates in our Healthcare section.
Source note: This article includes information reported by Business Plus.
Live Poll
Do you believe industry mergers and acquisitions generally lead to better service for customers?
